Sodium cromoglycate exerts anti-pulmonary fibrosis effects by targeting the Keap1 protein to activate Nrf2 signaling

[Display omitted] •Keap1-targeting binding compounds were identified by virtual screening.•It was certified that Cro could bind to the Keap1 protein directly in this research.•Cro can bind to the Keap1 to activate Nrf2 signaling and relieve oxidative stress.•Cro has potential anti-pulmonary fibrotic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bioorganic chemistry 2024-12, Vol.153, p.107961, Article 107961
Hauptverfasser: Liu, Xiaofeng, Huang, Yuwei, Zhao, Xianchen, Guan, Yingjun, Li, Yanchun, Yuan, Lei, Wang, Chuncheng, Ma, Chao, Ma, Enlong
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page 107961
container_title Bioorganic chemistry
container_volume 153
creator Liu, Xiaofeng
Huang, Yuwei
Zhao, Xianchen
Guan, Yingjun
Li, Yanchun
Yuan, Lei
Wang, Chuncheng
Ma, Chao
Ma, Enlong
description [Display omitted] •Keap1-targeting binding compounds were identified by virtual screening.•It was certified that Cro could bind to the Keap1 protein directly in this research.•Cro can bind to the Keap1 to activate Nrf2 signaling and relieve oxidative stress.•Cro has potential anti-pulmonary fibrotic activity in vitro and in vivo.•Cro can alleviate oxidative stress in the progression of pulmonary fibrosis. Oxidative stress has been confirmed to be closely related to the occurrence and development of pulmonary fibrosis (PF). The Kelch-like ECH-associated protein 1 (Keap1)-nuclear factor erythroid-2 related factor 2 (Nrf2) pathway plays a key role in maintaining cellular redox homeostasis. Targeting the Keap1 protein to activate Nrf2 could be a promising strategy for treating PF. Virtual screening via a pharmacophore model was used to screen candidate compounds with potential Keap1 binding ability from the U.S. Food and Drug Administration (FDA) database. The results revealed that sodium cromoglycate (Cro) has the highest fit value and absolute docking score and could improve the thermal stability of the Keap1 protein in a CETSA, confirming that Cro could bind to the Keap1 protein directly. Further studies revealed that Cro promoted Nrf2 translocation into the nucleus, relieved oxidative stress, prevented the epithelial-mesenchymal transition (EMT) process and upregulated fibrosis markers in TGF-β1-induced A549 cells, indicating that Cro has anti-pulmonary fibrosis activity in an in vitro lung fibrosis model. Moreover, in a mouse model of bleomycin (BLM)-induced pulmonary fibrosis, Cro administration improved pulmonary fibrosis, activated Nrf2 signaling, and blocked the EMT process. In summary, these results demonstrated that Cro could activate Nrf2 signaling to clear reactive oxygen species (ROS) by directly binding to Keap1 and alleviate pulmonary fibrosis by blocking the progression of EMT both in vitro and in vivo.
doi_str_mv 10.1016/j.bioorg.2024.107961
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3130207019</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0045206824008666</els_id><sourcerecordid>3130207019</sourcerecordid><originalsourceid>FETCH-LOGICAL-c241t-3fa7e9b8f27865eb7c4f28a9a58ab15d401525dd96ceb1bfdf84d54b80d54f9a3</originalsourceid><addsrcrecordid>eNp9kMtu1DAUQC1ERYfCHyDkJZsMtmMn8QYJVS0gqrIA1pYf18GjJB5sp-r8PR6lsGTjK_me-zoIvaFkTwnt3h_2JsSYxj0jjNevXnb0GdpRIknDKCPP0Y4QLhpGuuESvcz5QAilvO9eoMtWCtHJlu1Q-R5dWGdsU5zjOJ2sLoDhEVLJWC8lNMd1muOi0wn7YFLMIWPwHmzNmxMuOo1QwjLi8gvwV9BHio8pFggLLhFrW8LDueN98gznMC56qvArdOH1lOH1U7xCP29vflx_bu6-ffpy_fGusYzT0rRe9yDN4Fk_dAJMb7lng5ZaDNpQ4TihggnnZGfBUOOdH7gT3Aykvl7q9gq92_rWlX6vkIuaQ7YwTXqBuGbV0pYw0hMqK8o3tIrIOYFXxxTmeraiRJ19q4PafKuzb7X5rmVvnyasZgb3r-iv4Ap82ACodz4ESCrbAIsFF1KVqFwM_5_wB8YKlZo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3130207019</pqid></control><display><type>article</type><title>Sodium cromoglycate exerts anti-pulmonary fibrosis effects by targeting the Keap1 protein to activate Nrf2 signaling</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Liu, Xiaofeng ; Huang, Yuwei ; Zhao, Xianchen ; Guan, Yingjun ; Li, Yanchun ; Yuan, Lei ; Wang, Chuncheng ; Ma, Chao ; Ma, Enlong</creator><creatorcontrib>Liu, Xiaofeng ; Huang, Yuwei ; Zhao, Xianchen ; Guan, Yingjun ; Li, Yanchun ; Yuan, Lei ; Wang, Chuncheng ; Ma, Chao ; Ma, Enlong</creatorcontrib><description>[Display omitted] •Keap1-targeting binding compounds were identified by virtual screening.•It was certified that Cro could bind to the Keap1 protein directly in this research.•Cro can bind to the Keap1 to activate Nrf2 signaling and relieve oxidative stress.•Cro has potential anti-pulmonary fibrotic activity in vitro and in vivo.•Cro can alleviate oxidative stress in the progression of pulmonary fibrosis. Oxidative stress has been confirmed to be closely related to the occurrence and development of pulmonary fibrosis (PF). The Kelch-like ECH-associated protein 1 (Keap1)-nuclear factor erythroid-2 related factor 2 (Nrf2) pathway plays a key role in maintaining cellular redox homeostasis. Targeting the Keap1 protein to activate Nrf2 could be a promising strategy for treating PF. Virtual screening via a pharmacophore model was used to screen candidate compounds with potential Keap1 binding ability from the U.S. Food and Drug Administration (FDA) database. The results revealed that sodium cromoglycate (Cro) has the highest fit value and absolute docking score and could improve the thermal stability of the Keap1 protein in a CETSA, confirming that Cro could bind to the Keap1 protein directly. Further studies revealed that Cro promoted Nrf2 translocation into the nucleus, relieved oxidative stress, prevented the epithelial-mesenchymal transition (EMT) process and upregulated fibrosis markers in TGF-β1-induced A549 cells, indicating that Cro has anti-pulmonary fibrosis activity in an in vitro lung fibrosis model. Moreover, in a mouse model of bleomycin (BLM)-induced pulmonary fibrosis, Cro administration improved pulmonary fibrosis, activated Nrf2 signaling, and blocked the EMT process. In summary, these results demonstrated that Cro could activate Nrf2 signaling to clear reactive oxygen species (ROS) by directly binding to Keap1 and alleviate pulmonary fibrosis by blocking the progression of EMT both in vitro and in vivo.</description><identifier>ISSN: 0045-2068</identifier><identifier>ISSN: 1090-2120</identifier><identifier>EISSN: 1090-2120</identifier><identifier>DOI: 10.1016/j.bioorg.2024.107961</identifier><identifier>PMID: 39556932</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>A549 Cells ; Animals ; Antifibrotic Agents - chemical synthesis ; Antifibrotic Agents - chemistry ; Antifibrotic Agents - pharmacology ; Bleomycin ; Cromolyn Sodium - chemistry ; Cromolyn Sodium - pharmacology ; Dose-Response Relationship, Drug ; Humans ; Keap1-Nrf2 signaling ; Kelch-Like ECH-Associated Protein 1 - antagonists &amp; inhibitors ; Kelch-Like ECH-Associated Protein 1 - metabolism ; Male ; Mice ; Mice, Inbred C57BL ; Molecular Structure ; NF-E2-Related Factor 2 - antagonists &amp; inhibitors ; NF-E2-Related Factor 2 - metabolism ; Oxidative stress ; Oxidative Stress - drug effects ; Pulmonary fibrosis ; Pulmonary Fibrosis - chemically induced ; Pulmonary Fibrosis - drug therapy ; Pulmonary Fibrosis - metabolism ; Pulmonary Fibrosis - pathology ; Signal Transduction - drug effects ; Sodium cromoglycate ; Structure-Activity Relationship ; Virtual screening</subject><ispartof>Bioorganic chemistry, 2024-12, Vol.153, p.107961, Article 107961</ispartof><rights>2024 Elsevier Inc.</rights><rights>Copyright © 2024 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c241t-3fa7e9b8f27865eb7c4f28a9a58ab15d401525dd96ceb1bfdf84d54b80d54f9a3</cites><orcidid>0000-0002-6042-7212</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.bioorg.2024.107961$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39556932$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, Xiaofeng</creatorcontrib><creatorcontrib>Huang, Yuwei</creatorcontrib><creatorcontrib>Zhao, Xianchen</creatorcontrib><creatorcontrib>Guan, Yingjun</creatorcontrib><creatorcontrib>Li, Yanchun</creatorcontrib><creatorcontrib>Yuan, Lei</creatorcontrib><creatorcontrib>Wang, Chuncheng</creatorcontrib><creatorcontrib>Ma, Chao</creatorcontrib><creatorcontrib>Ma, Enlong</creatorcontrib><title>Sodium cromoglycate exerts anti-pulmonary fibrosis effects by targeting the Keap1 protein to activate Nrf2 signaling</title><title>Bioorganic chemistry</title><addtitle>Bioorg Chem</addtitle><description>[Display omitted] •Keap1-targeting binding compounds were identified by virtual screening.•It was certified that Cro could bind to the Keap1 protein directly in this research.•Cro can bind to the Keap1 to activate Nrf2 signaling and relieve oxidative stress.•Cro has potential anti-pulmonary fibrotic activity in vitro and in vivo.•Cro can alleviate oxidative stress in the progression of pulmonary fibrosis. Oxidative stress has been confirmed to be closely related to the occurrence and development of pulmonary fibrosis (PF). The Kelch-like ECH-associated protein 1 (Keap1)-nuclear factor erythroid-2 related factor 2 (Nrf2) pathway plays a key role in maintaining cellular redox homeostasis. Targeting the Keap1 protein to activate Nrf2 could be a promising strategy for treating PF. Virtual screening via a pharmacophore model was used to screen candidate compounds with potential Keap1 binding ability from the U.S. Food and Drug Administration (FDA) database. The results revealed that sodium cromoglycate (Cro) has the highest fit value and absolute docking score and could improve the thermal stability of the Keap1 protein in a CETSA, confirming that Cro could bind to the Keap1 protein directly. Further studies revealed that Cro promoted Nrf2 translocation into the nucleus, relieved oxidative stress, prevented the epithelial-mesenchymal transition (EMT) process and upregulated fibrosis markers in TGF-β1-induced A549 cells, indicating that Cro has anti-pulmonary fibrosis activity in an in vitro lung fibrosis model. Moreover, in a mouse model of bleomycin (BLM)-induced pulmonary fibrosis, Cro administration improved pulmonary fibrosis, activated Nrf2 signaling, and blocked the EMT process. In summary, these results demonstrated that Cro could activate Nrf2 signaling to clear reactive oxygen species (ROS) by directly binding to Keap1 and alleviate pulmonary fibrosis by blocking the progression of EMT both in vitro and in vivo.</description><subject>A549 Cells</subject><subject>Animals</subject><subject>Antifibrotic Agents - chemical synthesis</subject><subject>Antifibrotic Agents - chemistry</subject><subject>Antifibrotic Agents - pharmacology</subject><subject>Bleomycin</subject><subject>Cromolyn Sodium - chemistry</subject><subject>Cromolyn Sodium - pharmacology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Humans</subject><subject>Keap1-Nrf2 signaling</subject><subject>Kelch-Like ECH-Associated Protein 1 - antagonists &amp; inhibitors</subject><subject>Kelch-Like ECH-Associated Protein 1 - metabolism</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Molecular Structure</subject><subject>NF-E2-Related Factor 2 - antagonists &amp; inhibitors</subject><subject>NF-E2-Related Factor 2 - metabolism</subject><subject>Oxidative stress</subject><subject>Oxidative Stress - drug effects</subject><subject>Pulmonary fibrosis</subject><subject>Pulmonary Fibrosis - chemically induced</subject><subject>Pulmonary Fibrosis - drug therapy</subject><subject>Pulmonary Fibrosis - metabolism</subject><subject>Pulmonary Fibrosis - pathology</subject><subject>Signal Transduction - drug effects</subject><subject>Sodium cromoglycate</subject><subject>Structure-Activity Relationship</subject><subject>Virtual screening</subject><issn>0045-2068</issn><issn>1090-2120</issn><issn>1090-2120</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtu1DAUQC1ERYfCHyDkJZsMtmMn8QYJVS0gqrIA1pYf18GjJB5sp-r8PR6lsGTjK_me-zoIvaFkTwnt3h_2JsSYxj0jjNevXnb0GdpRIknDKCPP0Y4QLhpGuuESvcz5QAilvO9eoMtWCtHJlu1Q-R5dWGdsU5zjOJ2sLoDhEVLJWC8lNMd1muOi0wn7YFLMIWPwHmzNmxMuOo1QwjLi8gvwV9BHio8pFggLLhFrW8LDueN98gznMC56qvArdOH1lOH1U7xCP29vflx_bu6-ffpy_fGusYzT0rRe9yDN4Fk_dAJMb7lng5ZaDNpQ4TihggnnZGfBUOOdH7gT3Aykvl7q9gq92_rWlX6vkIuaQ7YwTXqBuGbV0pYw0hMqK8o3tIrIOYFXxxTmeraiRJ19q4PafKuzb7X5rmVvnyasZgb3r-iv4Ap82ACodz4ESCrbAIsFF1KVqFwM_5_wB8YKlZo</recordid><startdate>202412</startdate><enddate>202412</enddate><creator>Liu, Xiaofeng</creator><creator>Huang, Yuwei</creator><creator>Zhao, Xianchen</creator><creator>Guan, Yingjun</creator><creator>Li, Yanchun</creator><creator>Yuan, Lei</creator><creator>Wang, Chuncheng</creator><creator>Ma, Chao</creator><creator>Ma, Enlong</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6042-7212</orcidid></search><sort><creationdate>202412</creationdate><title>Sodium cromoglycate exerts anti-pulmonary fibrosis effects by targeting the Keap1 protein to activate Nrf2 signaling</title><author>Liu, Xiaofeng ; Huang, Yuwei ; Zhao, Xianchen ; Guan, Yingjun ; Li, Yanchun ; Yuan, Lei ; Wang, Chuncheng ; Ma, Chao ; Ma, Enlong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c241t-3fa7e9b8f27865eb7c4f28a9a58ab15d401525dd96ceb1bfdf84d54b80d54f9a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>A549 Cells</topic><topic>Animals</topic><topic>Antifibrotic Agents - chemical synthesis</topic><topic>Antifibrotic Agents - chemistry</topic><topic>Antifibrotic Agents - pharmacology</topic><topic>Bleomycin</topic><topic>Cromolyn Sodium - chemistry</topic><topic>Cromolyn Sodium - pharmacology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Humans</topic><topic>Keap1-Nrf2 signaling</topic><topic>Kelch-Like ECH-Associated Protein 1 - antagonists &amp; inhibitors</topic><topic>Kelch-Like ECH-Associated Protein 1 - metabolism</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Molecular Structure</topic><topic>NF-E2-Related Factor 2 - antagonists &amp; inhibitors</topic><topic>NF-E2-Related Factor 2 - metabolism</topic><topic>Oxidative stress</topic><topic>Oxidative Stress - drug effects</topic><topic>Pulmonary fibrosis</topic><topic>Pulmonary Fibrosis - chemically induced</topic><topic>Pulmonary Fibrosis - drug therapy</topic><topic>Pulmonary Fibrosis - metabolism</topic><topic>Pulmonary Fibrosis - pathology</topic><topic>Signal Transduction - drug effects</topic><topic>Sodium cromoglycate</topic><topic>Structure-Activity Relationship</topic><topic>Virtual screening</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Xiaofeng</creatorcontrib><creatorcontrib>Huang, Yuwei</creatorcontrib><creatorcontrib>Zhao, Xianchen</creatorcontrib><creatorcontrib>Guan, Yingjun</creatorcontrib><creatorcontrib>Li, Yanchun</creatorcontrib><creatorcontrib>Yuan, Lei</creatorcontrib><creatorcontrib>Wang, Chuncheng</creatorcontrib><creatorcontrib>Ma, Chao</creatorcontrib><creatorcontrib>Ma, Enlong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Bioorganic chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Xiaofeng</au><au>Huang, Yuwei</au><au>Zhao, Xianchen</au><au>Guan, Yingjun</au><au>Li, Yanchun</au><au>Yuan, Lei</au><au>Wang, Chuncheng</au><au>Ma, Chao</au><au>Ma, Enlong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sodium cromoglycate exerts anti-pulmonary fibrosis effects by targeting the Keap1 protein to activate Nrf2 signaling</atitle><jtitle>Bioorganic chemistry</jtitle><addtitle>Bioorg Chem</addtitle><date>2024-12</date><risdate>2024</risdate><volume>153</volume><spage>107961</spage><pages>107961-</pages><artnum>107961</artnum><issn>0045-2068</issn><issn>1090-2120</issn><eissn>1090-2120</eissn><abstract>[Display omitted] •Keap1-targeting binding compounds were identified by virtual screening.•It was certified that Cro could bind to the Keap1 protein directly in this research.•Cro can bind to the Keap1 to activate Nrf2 signaling and relieve oxidative stress.•Cro has potential anti-pulmonary fibrotic activity in vitro and in vivo.•Cro can alleviate oxidative stress in the progression of pulmonary fibrosis. Oxidative stress has been confirmed to be closely related to the occurrence and development of pulmonary fibrosis (PF). The Kelch-like ECH-associated protein 1 (Keap1)-nuclear factor erythroid-2 related factor 2 (Nrf2) pathway plays a key role in maintaining cellular redox homeostasis. Targeting the Keap1 protein to activate Nrf2 could be a promising strategy for treating PF. Virtual screening via a pharmacophore model was used to screen candidate compounds with potential Keap1 binding ability from the U.S. Food and Drug Administration (FDA) database. The results revealed that sodium cromoglycate (Cro) has the highest fit value and absolute docking score and could improve the thermal stability of the Keap1 protein in a CETSA, confirming that Cro could bind to the Keap1 protein directly. Further studies revealed that Cro promoted Nrf2 translocation into the nucleus, relieved oxidative stress, prevented the epithelial-mesenchymal transition (EMT) process and upregulated fibrosis markers in TGF-β1-induced A549 cells, indicating that Cro has anti-pulmonary fibrosis activity in an in vitro lung fibrosis model. Moreover, in a mouse model of bleomycin (BLM)-induced pulmonary fibrosis, Cro administration improved pulmonary fibrosis, activated Nrf2 signaling, and blocked the EMT process. In summary, these results demonstrated that Cro could activate Nrf2 signaling to clear reactive oxygen species (ROS) by directly binding to Keap1 and alleviate pulmonary fibrosis by blocking the progression of EMT both in vitro and in vivo.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>39556932</pmid><doi>10.1016/j.bioorg.2024.107961</doi><orcidid>https://orcid.org/0000-0002-6042-7212</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0045-2068
ispartof Bioorganic chemistry, 2024-12, Vol.153, p.107961, Article 107961
issn 0045-2068
1090-2120
1090-2120
language eng
recordid cdi_proquest_miscellaneous_3130207019
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects A549 Cells
Animals
Antifibrotic Agents - chemical synthesis
Antifibrotic Agents - chemistry
Antifibrotic Agents - pharmacology
Bleomycin
Cromolyn Sodium - chemistry
Cromolyn Sodium - pharmacology
Dose-Response Relationship, Drug
Humans
Keap1-Nrf2 signaling
Kelch-Like ECH-Associated Protein 1 - antagonists & inhibitors
Kelch-Like ECH-Associated Protein 1 - metabolism
Male
Mice
Mice, Inbred C57BL
Molecular Structure
NF-E2-Related Factor 2 - antagonists & inhibitors
NF-E2-Related Factor 2 - metabolism
Oxidative stress
Oxidative Stress - drug effects
Pulmonary fibrosis
Pulmonary Fibrosis - chemically induced
Pulmonary Fibrosis - drug therapy
Pulmonary Fibrosis - metabolism
Pulmonary Fibrosis - pathology
Signal Transduction - drug effects
Sodium cromoglycate
Structure-Activity Relationship
Virtual screening
title Sodium cromoglycate exerts anti-pulmonary fibrosis effects by targeting the Keap1 protein to activate Nrf2 signaling
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T14%3A06%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sodium%20cromoglycate%20exerts%20anti-pulmonary%20fibrosis%20effects%20by%20targeting%20the%20Keap1%20protein%20to%20activate%20Nrf2%20signaling&rft.jtitle=Bioorganic%20chemistry&rft.au=Liu,%20Xiaofeng&rft.date=2024-12&rft.volume=153&rft.spage=107961&rft.pages=107961-&rft.artnum=107961&rft.issn=0045-2068&rft.eissn=1090-2120&rft_id=info:doi/10.1016/j.bioorg.2024.107961&rft_dat=%3Cproquest_cross%3E3130207019%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3130207019&rft_id=info:pmid/39556932&rft_els_id=S0045206824008666&rfr_iscdi=true